Oncotarget

Research Papers:

Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer

Farhad Ghasemi, Morgan Black, Frederick Vizeacoumar, Nicole Pinto, Kara M. Ruicci, Carson Cao Son Huu Le, Matthew R. Lowerison, Hon Sing Leong, John Yoo, Kevin Fung, Danielle MacNeil, David A. Palma, Eric Winquist, Joe S. Mymryk, Paul C. Boutros, Alessandro Datti, John W. Barrett and Anthony C. Nichols _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:71512-71519. https://doi.org/10.18632/oncotarget.17292

Metrics: PDF 1520 views  |   HTML 3913 views  |   ?  


Abstract

Farhad Ghasemi1, Morgan Black1,2, Frederick Vizeacoumar3, Nicole Pinto1,2, Kara M. Ruicci1,2, Carson Cao Son Huu Le4,5, Matthew R. Lowerison6,7, Hon Sing Leong4,5, John Yoo1,2, Kevin Fung1,2, Danielle MacNeil1,2, David A. Palma2, Eric Winquist2, Joe S. Mymryk1,2,8, Paul C. Boutros9,10, Alessandro Datti3, John W. Barrett1,2 and Anthony C. Nichols1,2

1Department of Otolaryngology, London Health Sciences Centre, London, Ontario, Canada

2Department of Oncology, London Health Sciences Centre, London, Ontario, Canada

3Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

4Department of Surgery, Schulich School of Medicine, Western University, London, Ontario, Canada

5Translational Prostate Cancer Research Laboratory, Lawson Health Research Institute, London, Ontario, Canada

6Department of Medical Biophysics, Western University, London, Ontario, Canada

7Robarts Research Institute, Western University, London, Ontario, Canada

8Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada

9Informatics and Biocomputing Program, Ontario Institute of Cancer Research, MaRS Centre, Toronto, Ontario, Canada

10Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

Correspondence to:

Anthony C. Nichols, email: Anthony.Nichols@lhsc.on.ca

Keywords: head and neck cancer, human papillomavirus, anti-helminthic, cell cycle arrest

Received: September 24, 2016     Accepted: April 11, 2017     Published: April 20, 2017

ABSTRACT

Albendazole is an anti-helminthic drug that has been shown to exhibit anti-cancer properties, however its activity in head and neck squamous cell cancer (HNSCC) was unknown. Using a series of in vitro assays, we assessed the ability of albendazole to inhibit proliferation in 20 HNSCC cell lines across a range of albendazole doses (1 nM–10 μM). Cell lines that responded to treatment were further examined for cell death, inhibition of migration and cell cycle arrest. Thirteen of fourteen human papillomavirus-negative HNSCC cell lines responded to albendazole, with an average IC50 of 152 nM. In contrast, only 3 of 6 human papillomavirus-positive HNSCC cell lines responded. Albendazole treatment resulted in apoptosis, inhibition of cell migration, cell cycle arrest in the G2/M phase and altered tubulin distribution. Normal control cells were not measurably affected by any dose tested. This study indicates that albendazole acts to inhibit the proliferation of human papillomavirus-negative HNSCC cell lines and thus warrants further study as a potential chemotherapeutic agent for patients suffering from head and neck cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17292